Distinct regions harboring cancer stem cells (CSCs) have been identified within the
microenvironment of various tumors, and as in the case of their healthy counterparts, these …

Compelling evidence have demonstrated that bulk tumors can arise from a unique subset of
cells commonly termed “cancer stem cells” that has been proposed to be a strong driving …

HCC comprises∼ 80% of primary liver cancer. HCC is the only major cancer for which death
rates have not improved over the last 10 years. Most patients are diagnosed with advanced …

The survival benefit derived from sorafenib treatment for patients with hepatocellular
carcinoma (HCC) is modest due to acquired resistance. Targeting cancer stem cells (CSC) …

Hepatocellular carcinoma (HCC) remains one of the most common and lethal malignancies
worldwide despite the development of various therapeutic strategies. A better understanding …

Liver cancer is the second most common cause of cancer-related death. The major forms of
primary liver cancer are hepatocellular carcinoma (HCC) and intrahepatic …

Sorafenib is a new standard treatment for patients with advanced hepatocellular carcinoma
(HCC). However, the survival benefit of this treatment is modest, partly owing to drug …

Although cancer stem cells have been well characterized in numerous malignancies, the
fundamental characteristics of this group of cells, however, have been challenged by some …

Liver cancer has no effective therapies, hence a poor survival. Cancer stem-like cells not
only contribute to cancer initiation and progression, but also to drug resistance, cancer …

Aldehyde dehydrogenases 1 family member A1 (ALDH1A1) gene codes a cytoplasmic
enzyme and shows vital physiological and pathophysiological functions in many areas …